Patches containing rotigotine
By adding specific combinations of resins and alcohols to the adhesive layer of the rotigotine adhesive agent, the ratio of crosslinked polyvinylpyrrolidone is controlled, and the problem of easy crystallization of rotigotine is solved, achieving high permeability and Long-term stable rotigotine adhesion.
Patent Information
- Application Number
- CN201880082300.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-31
- Filing Date
- 2018-12-14
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2038-12-14
AI Technical Summary
Among the existing rotigotine adhesion agents, amorphous rotigotine is easily transformed into crystalline form, resulting in a decrease in skin permeability, and it is difficult to achieve sufficient rotigotine permeability using antioxidants and other methods. stability.
Add styrene-based thermoplastic elastomer, petroleum-based resin, terpene-based resin, aliphatic alcohol and crosslinked polyvinylpyrrolidone to the adhesive layer, and control the blending ratio to completely dissolve rotigotine and its salt to prevent crystallization Precipitate.
The high-level skin permeability and long-term stability of rotigotine are achieved, crystallization precipitation is avoided, and excellent permeability and physical stability are maintained.
Smart Images

Figure CN111491622B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a patch containing rotigotine, and more particularly, to a patch containing rotigotine and / or a pharmaceutically acceptable salt thereof. Background Art
[0002] Rotigotine is the international common name of the compound (-)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]-amino]-1-naphthol, and Japanese Patent Publication No. 2011-504902 (Patent Document 1) states that there are type I and type II polymorphs. Rotigotine is a D1 / D2 / D3 dopamine receptor agonist and is mainly used to treat the symptoms of Parkinson's disease and restless legs syndrome.
[0003] As a preparation for administering rotigotine, for example, "Nypro (registered trademark) patch" is commercially available at home and abroad. In addition, Japanese Patent Publication No. 2002-509878 (Patent Document 2) describes a transdermal therapeutic system, which includes a backing layer that is inactive relative to the components of the matrix and a self-adhesive matrix layer containing rotigotine, the solubility of rotigotine in the matrix is 5% (w / w) or more, and a water-insoluble acrylate-based or silicone-based polymer adhesive is used as a base material. Furthermore, Japanese Patent Publication No. 2015-503541 (Patent Document 3) describes a transdermal therapeutic system, which includes a backing layer that is impermeable to active substances and a matrix layer containing particles of a pressure-sensitive adhesive, a drug, and cross-linked polyvinyl pyrrolidone, rotigotine is described as the above-mentioned drug, and a silicone polymer is described as the above-mentioned pressure-sensitive adhesive.
[0004] In addition, as preparations for administering rotigotine using a rubber-based adhesive, for example, Japanese Patent Application Laid-Open No. 2014-177428 (Patent Document 4) describes a percutaneous patch preparation comprising a support and a drug-containing layer, wherein the drug-containing layer contains: a rubber-based adhesive containing a rosin-based resin and a rubber-based adhesive component, and rotigotine or a pharmaceutically acceptable salt thereof; Japanese Patent Application Laid-Open No. 2013-079220 (Patent Document 5) describes a percutaneous patch preparation comprising a support and a drug-containing layer, wherein the drug-containing layer contains a rubber-based adhesive, rotigotine or a salt thereof, and an inhibitor for the production of decomposition products of rotigotine.
[0005] Furthermore, as preparations for administering rotigotine, for example, Japanese Patent Publication No. 2006-513195 (Patent Document 6) and Japanese Patent Publication No. 2012-504609 (Patent Document 7) describe preparations containing rotigotine in an amorphous (non-crystalline) form; Japanese Patent Publication No. 2013-515041 (Patent Document 8) describes a method for stabilizing rotigotine, which comprises the following steps: using polyvinyl pyrrolidone (non-crosslinked) at a specific weight ratio relative to rotigotine to provide a solid dispersion containing polyvinyl pyrrolidone and rotigotine in an amorphous form.
[0006] In addition, Japanese Patent Publication No. 2013-510805 (Patent Document 9) describes that as a method for preventing crystallization of a drug in a polymer film, a coating material containing a solvent applied to produce a polymer film is dried at a temperature that is always at least 10° C. higher than the melting temperature of the drug present therein. Furthermore, Japanese Patent Publication No. 2017-515871 (Patent Document 10) describes a method for producing a percutaneous absorption preparation in which “rotigotine and an antioxidant are mixed at a specific weight ratio for the purpose of preventing rotigotine from crystallizing.”
[0007] Prior art literature
[0008] Patent Literature
[0009] Patent Document 1: Japanese Patent Application No. 2011-504902
[0010] Patent Document 2: Japanese Patent Application No. 2002-509878
[0011] Patent Document 3: Japanese Patent Application No. 2015-503541
[0012] Patent Document 4: Japanese Patent Application Publication No. 2014-177428
[0013] Patent Document 5: Japanese Patent Application Publication No. 2013-079220
[0014] Patent Document 6: Japanese Patent Application No. 2006-513195
[0015] Patent Document 7: Japanese Patent Application No. 2012-504609
[0016] Patent Document 8: Japanese Patent Application No. 2013-515041
[0017] Patent Document 9: Japanese Patent Application No. 2013-510805
[0018] Patent Document 10: Japanese Patent Application No. 2017-515871 Summary of the invention
[0019] Problems to be solved by the invention
[0020] However, in the case of rotigotine-containing patches containing rotigotine and / or a pharmaceutically acceptable salt thereof, as in the preparations described in Patent Documents 6 to 8, when rotigotine is contained in an amorphous form alone or in the presence of polyvinyl pyrrolidone, the amorphous form is in an energetically metastable state, and thus there is a problem that it may be converted into an energetically more stable crystalline form over time and crystals may be precipitated. Furthermore, the production method including specific conditions and steps as described in Patent Document 9 may be complicated and increase the production cost, and even if an antioxidant as described in Patent Document 10 is simply used, there is a problem that sufficient skin permeability of rotigotine may not be achieved.
[0021] In addition, the present inventors conducted further studies and found that, in a patch containing rotigotine having a support layer and an adhesive layer, as an adhesive base to be contained in the adhesive layer, silicone-based adhesive bases and acrylic adhesives that have been commonly used in combination with rotigotine have been used, or even if a rubber-based adhesive such as polyisobutylene is simply used, rotigotine and / or its pharmaceutically acceptable salts do not dissolve, or even if they are temporarily dissolved, crystals derived from rotigotine and / or its pharmaceutically acceptable salts precipitate over time, making it difficult to contain rotigotine and / or its pharmaceutically acceptable salts in a dissolved form in the adhesive layer. In addition, the present inventors also found that, in order to dissolve such crystals, if a solubilizing agent or the like that has been known to dissolve crystals is simply used, the skin permeability of rotigotine is reduced.
[0022] The present invention has been made in view of the above problems, and an object of the present invention is to provide a patch comprising rotigotine and / or a pharmaceutically acceptable salt thereof in a dissolved form in an adhesive layer and having excellent stability over time and skin permeability of rotigotine.
[0023] Methods for solving problems
[0024] The present inventors have conducted intensive studies to achieve the above-mentioned object, and as a result, have found that, in a patch having a support layer and an adhesive layer, the adhesive layer contains at least one selected from rotigotine and its pharmaceutically acceptable salts (hereinafter referred to as "rotigotine and / or its pharmaceutically acceptable salts"), a styrene-based thermoplastic elastomer, at least one selected from petroleum-based resins and terpene-based resins (hereinafter referred to as "petroleum-based resins and / or terpene-based resins"), an aliphatic alcohol, and a cross-linked polyvinyl pyrrolidone, and further, the blending ratio (mass ratio) of rotigotine and / or its pharmaceutically acceptable salt to the cross-linked polyvinyl pyrrolidone is within a specific range, thereby enabling rotigotine and / or its pharmaceutically acceptable salt to be contained in the adhesive layer in a completely dissolved form.
[0025] Furthermore, the present inventors have found that in a rotigotine-containing patch having such a structure, a high level of skin permeability of rotigotine is achieved, and further, even if a long period of time has passed since the production, crystals of rotigotine and / or a pharmaceutically acceptable salt thereof are not precipitated, so that the above-mentioned excellent skin permeability and preparation properties are maintained and temporal stability is exhibited, thereby completing the present invention.
[0026] That is, the rotigotine-containing patch of the present invention comprises a support layer and an adhesive layer, wherein the adhesive layer contains rotigotine and / or a pharmaceutically acceptable salt thereof.
[0027] The adhesive layer further comprises a styrene-based thermoplastic elastomer, a petroleum-based resin and / or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinyl pyrrolidone, and
[0028] In the adhesive layer, the mass ratio of the content of rotigotine and / or its pharmaceutically acceptable salt converted into rotigotine free body to the content of cross-linked polyvinyl pyrrolidone (rotigotine free body content of rotigotine and / or its pharmaceutically acceptable salt converted into rotigotine:cross-linked polyvinyl pyrrolidone content) is 10:3 to 1:3.
[0029] In the rotigotine-containing patch of the present invention, the adhesive layer preferably contains rotigotine and / or a pharmaceutically acceptable salt thereof in a dissolved form. In addition, the aliphatic alcohol preferably has 12 to 23 carbon atoms.
[0030] Furthermore, in the rotigotine-containing patch of the present invention, the content of rotigotine and / or a pharmaceutically acceptable salt thereof in the adhesive layer, calculated as a free form of rotigotine, is preferably 5 to 15% by mass relative to the total mass of the adhesive layer, the content of the petroleum-based resin and / or the terpene-based resin in the adhesive layer is preferably 5 to 80% by mass relative to the total mass of the adhesive layer, and the content of the aliphatic alcohol in the adhesive layer is preferably 1 to 15% by mass relative to the total mass of the adhesive layer.
[0031] In the rotigotine-containing patch of the present invention, it is preferred that the adhesive layer further contains a stabilizer.
[0032] In addition, in the present invention, the so-called "dissolved drug" refers to a state in which the drug is diffused in the adhesive layer in the form of molecules at room temperature (25°C). The drug being dissolved can be confirmed as follows: no baseline drift (shift) caused by the endothermic melting point peak derived from crystals and the glass transition derived from amorphous substances is observed in differential scanning calorimetry (DSC). In the case where the above-mentioned drug is rotigotine free body, the above-mentioned endothermic melting point peak (melting point) can be obtained from the peak observed in the differential thermal analysis chart obtained by heating the crystals of the drug from 10°C to 120°C at a heating rate of 10°C / min using a differential scanning calorimeter and performing DSC measurement, for example, Figures 1-2 As shown, when the crystals of free rotigotine are in type I, at around 78°C ( Figure 1 ) an endothermic melting point peak was observed, and in the case where the crystals of rotigotine free form were type II, the melting point peak was observed at around 97°C ( Figure 2 ) an endothermic melting point peak is observed. Furthermore, the baseline shift caused by the glass transition can be obtained by the baseline shift observed in the differential thermal analysis chart obtained by heating the amorphous drug from 10°C to 120°C at a heating rate of 10°C / min using a differential scanning calorimeter and performing DSC measurement. In addition, for example, when the drug is rotigotine hydrochloride, the baseline shift caused by the endothermic melting point peak and the glass transition can be obtained by performing DSC measurement in the same manner as above except that the heating temperature is changed from 10°C to 190°C, and obtaining a differential thermal analysis chart, and obtaining the baseline shift from the peaks observed in the chart.
[0033] Effects of the Invention
[0034] According to the present invention, a rotigotine-containing patch can be provided, which contains rotigotine and / or a pharmaceutically acceptable salt thereof in a dissolved form in an adhesive layer and has excellent stability over time and skin permeability of rotigotine. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1This is a diagram showing the results of DSC measurement of type I crystals of free rotigotine.
[0036] Figure 2 This is a diagram showing the results of DSC measurement of type II crystals of free rotigotine.
[0037] Figure 3 This is a graph showing the results of DSC measurement of the adhesive layer of the patch obtained in Example 3 six months after the production. DETAILED DESCRIPTION
[0038] The present invention will be described in detail below based on its preferred embodiments. The rotigotine-containing patch of the present invention is a patch comprising a support layer and an adhesive layer, wherein the adhesive layer contains rotigotine and / or a pharmaceutically acceptable salt thereof.
[0039] The adhesive layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and / or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinyl pyrrolidone, and
[0040] In the adhesive layer, the mass ratio of the content of rotigotine and / or its pharmaceutically acceptable salt converted into rotigotine free body to the content of cross-linked polyvinyl pyrrolidone (rotigotine free body content of rotigotine and / or its pharmaceutically acceptable salt converted into rotigotine:cross-linked polyvinyl pyrrolidone content) is 10:3 to 1:3.
[0041] The patch containing rotigotine of the present invention has a support layer and an adhesive layer. As the above-mentioned support layer, there is no particular limitation as long as it can support the adhesive layer described later. As the support layer of the patch, a known support layer can be appropriately used. As the material of the support layer involved in the present invention, for example, polyolefins such as polyethylene and polypropylene; ethylene-vinyl acetate copolymers, vinyl acetate-vinyl chloride copolymers, polyvinyl chloride, etc.; polyamides such as nylon; polyesters such as polyethylene terephthalate (PET), polybutylene terephthalate, and polyethylene naphthalate; cellulose derivatives; synthetic resins such as polyurethane, and metals such as aluminum. Among them, from the viewpoint of drug non-adsorbability and drug non-permeability, polyester and polyethylene terephthalate are preferred. As the form of the above-mentioned support layer, for example, films; sheets such as sheets, sheet-like porous bodies, and sheet-like foams; fabrics such as fabrics, woven fabrics, and non-woven fabrics; foils; and their laminates. The thickness of the support layer is not particularly limited, but is preferably within a range of 5 to 1000 μm from the viewpoint of ease of handling when applying the patch and ease of production.
[0042] The rotigotine-containing patch of the present invention may further include a release liner on the surface of the adhesive layer opposite to the support layer. Examples of such a release liner include films, sheets, and laminates thereof formed of polyolefins such as polyethylene and polypropylene; ethylene-vinyl acetate copolymers, vinyl acetate-vinyl chloride copolymers, polyvinyl chloride, etc.; polyamides such as nylon; polyesters such as polyethylene terephthalate; cellulose derivatives; synthetic resins such as polyurethane, aluminum, paper, and the like. In order to facilitate the release of these release liners from the adhesive layer, it is preferred that the surface on the side in contact with the adhesive layer be subjected to a release treatment such as coating with an organic silicon compound or coating with a fluorine compound.
[0043] <Rotigotine and its pharmaceutically acceptable salts>
[0044] The adhesive layer of the present invention contains at least one selected from rotigotine and its pharmaceutically acceptable salt as a drug. In the present invention, the form of rotigotine contained in the above-mentioned adhesive layer can be a free body (free body), or a pharmaceutically acceptable salt thereof, or a substance in which the pharmaceutically acceptable salt of rotigotine is desalted in the preparation during manufacture and / or manufactured to become a free body, and can be one of them or a mixture of two or more. As the pharmaceutically acceptable salt of rotigotine, acid addition salts can be cited, and as the acid of the above-mentioned acid addition salt, for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phosphorous acid, hydrobromic acid, maleic acid, malic acid, ascorbic acid, tartaric acid, lauric acid, stearic acid, palmitic acid, oleic acid, myristic acid, lauryl sulfuric acid, linolenic acid, fumaric acid can be cited. Among them, as the adhesive layer of the present invention, it is preferred to contain rotigotine in the form of a free body.
[0045] In the present invention, the content of rotigotine and / or a pharmaceutically acceptable salt thereof contained in the adhesive layer (the content of rotigotine or the content of a pharmaceutically acceptable salt thereof, or the total content thereof when both are contained, the same shall apply hereinafter) is preferably 5 to 15% by mass, more preferably 7 to 12% by mass, and still more preferably 8 to 10% by mass, based on the total mass of the adhesive layer in terms of free rotigotine. If the content of rotigotine and / or a pharmaceutically acceptable salt thereof is less than the above lower limit, the skin permeability of rotigotine tends to decrease, while if the content exceeds the above upper limit, crystals of rotigotine and / or a pharmaceutically acceptable salt thereof tend to precipitate, or an amorphous form tends to be generated, or the adhesive force of the adhesive layer tends to decrease.
[0046] <Styrene-based thermoplastic elastomer>
[0047] The adhesive layer of the present invention contains a styrene-based thermoplastic elastomer as an adhesive base. In the configuration of the present invention, if the styrene-based thermoplastic elastomer is contained in the adhesive layer, rotigotine and / or a pharmaceutically acceptable salt thereof can be contained in the adhesive layer in a more stable dissolved form.
[0048] The so-called styrene-based thermoplastic elastomer of the present invention is a styrene-based elastomer showing thermoplasticity, which means that it softens and shows fluidity when heated and returns to a rubbery state when cooled. Among them, styrene-based block copolymers are preferred from the viewpoint of imparting sufficient adhesiveness and stability over time.
[0049] As the above-mentioned styrene-based block copolymer, specifically, styrene-butadiene block copolymer, styrene-butadiene-styrene block copolymer (SBS), styrene-isoprene block copolymer, styrene-isoprene-styrene block copolymer (SIS), styrene-ethylene / butylene block copolymer, styrene-ethylene / butylene-styrene block copolymer, styrene-ethylene / propylene block copolymer, styrene-ethylene / propylene-styrene block copolymer, styrene-isobutylene block copolymer, styrene-isobutylene-styrene block copolymer, etc. can be cited, and one of them can be used alone, or two or more can be used in combination. In addition, in the above, "ethylene / butylene" means a copolymer block of ethylene and butene, and "ethylene / propylene" means a copolymer block of ethylene and propylene. Among them, as the styrene-based thermoplastic elastomer involved in the present invention, styrene-isoprene-styrene block copolymer is more preferably used.
[0050] The viscosity average molecular weight of the styrene-isoprene-styrene block copolymer is preferably 30,000 to 2,500,000, and more preferably 100,000 to 1,700,000. If the viscosity average molecular weight is less than the lower limit, the preparation properties of the patch (particularly the cohesive force of the adhesive layer) tend to be reduced, while if it exceeds the upper limit, the compatibility with other components contained in the adhesive layer tends to be reduced, and the manufacture of the patch tends to become difficult.
[0051] In the present invention, the content of the styrene-based thermoplastic elastomer contained in the adhesive layer is preferably 5 to 50% by mass, more preferably 10 to 40% by mass, and further preferably 10 to 30% by mass relative to the total mass of the adhesive layer. If the content of the styrene-based thermoplastic elastomer is less than the lower limit, the cohesive force and shape retention of the adhesive layer tend to decrease, while if the content exceeds the upper limit, the cohesive force of the adhesive layer tends to increase excessively, and the adhesive force or compatibility of the adhesive layer tends to decrease.
[0052] <Petroleum-based resin / terpene-based resin>
[0053] The adhesive layer of the present invention further contains at least one selected from a petroleum resin and a terpene resin. In the present invention, by containing the petroleum resin and / or the terpene resin, a high level of skin permeability is achieved, and further, the generation of rotigotine analogs is further suppressed, and the stability over time is further improved.
[0054] (Petroleum-based resin)
[0055] Examples of the petroleum-based resins involved in the present invention include C5-based synthetic petroleum resins (copolymers of at least two of isoprene, cyclopentadiene, 1,3-pentadiene, and 1-pentene; copolymers of at least two of 2-pentene and dicyclopentadiene; resins with 1,3-pentadiene as the main component, etc.), C9-based synthetic petroleum resins (copolymers of at least two of indene, styrene, methylindene, and α-methylstyrene, etc.), and dicyclopentadiene-based synthetic petroleum resins (copolymers of dicyclopentadiene as the main component with isoprene and / or 1,3-pentadiene). In addition, from the viewpoint of other classifications, for example, alicyclic petroleum resins (alicyclic saturated hydrocarbon resins, etc.), alicyclic hydrogenated petroleum resins, aliphatic petroleum resins (aliphatic hydrocarbon resins, etc.), aliphatic hydrogenated petroleum resins, aromatic petroleum resins, more specifically, Alcon P-70, Alcon P-85, Alcon P-90, Alcon P-100, Alcon P-115, Alcon P-125 (above, trade names, manufactured by Arakawa Chemical Industries, Ltd.), Escolex 8000 (trade name, manufactured by Esso Petrochemical Co., Ltd.) can be mentioned. As the petroleum resins to which the present invention relates, one of them can be used alone, or two or more of them can be used in combination. Among them, alicyclic saturated hydrocarbon resins are more preferred from the viewpoints that they can easily obtain adhesion suitable for the skin, have less odor and thus have a good feel during use, and furthermore, the production of rotigotine analogs is further suppressed.
[0056] In the present invention, the alicyclic saturated hydrocarbon resin refers to a resin which is a homopolymer or copolymer of an alicyclic saturated hydrocarbon monomer. The alicyclic saturated hydrocarbon resin preferably has a weight average molecular weight of 1,000 to 1,500, and more preferably 1,200 to 1,400.
[0057] (Terpene resin)
[0058] Examples of the terpene resins involved in the present invention include pinene polymers (α-pinene polymers, β-pinene polymers, etc.), terpene polymers, dipentene polymers, terpene-phenol polymers, aromatic modified terpene polymers, and pinene-phenol copolymers. More specifically, examples include YS resins (YS resin PXN (1150N, 300N), YS resin PX1000, YS resin TO125, YS resin TO105, etc.), Crystalon P105, Crystalon M115, Crystalon K100 (these are trade names, manufactured by Yashara Chemical Co., Ltd.), and Tamanol 901 (trade name, manufactured by Arakawa Chemical Industries, Ltd.). Any one of these may be used alone, or two or more of them may be used in combination. Among them, as the terpene resin according to the present invention, a pinene polymer is more preferable from the viewpoint that it is easy to obtain favorable adhesion to the skin and has less odor and thus a good feeling during use.
[0059] In the present invention, the content of the petroleum resin and / or terpene resin contained in the adhesive layer (the content of the petroleum resin or the terpene resin, or the total content when both are contained, the same below) is preferably 5 to 80% by mass, more preferably 10 to 70% by mass, further preferably 10 to 60% by mass, and particularly preferably 20 to 60% by mass relative to the total mass of the adhesive layer. If the content of the petroleum resin and / or the terpene resin is less than the lower limit, the adhesive force and adhesion to the skin of the adhesive layer tend to be reduced, or the effect of inhibiting the generation of rotigotine analogs tends to be insufficient. On the other hand, if the content exceeds the upper limit, the transdermal absorbability of the drug and the shape retention of the adhesive layer tend to be reduced.
[0060] <Aliphatic alcohol>
[0061] The adhesive layer according to the present invention further contains an aliphatic alcohol. In the present invention, the aliphatic alcohol refers to a saturated or unsaturated, linear or branched, monovalent or divalent or higher aliphatic alcohol.
[0062] The aliphatic alcohol used in the present invention is preferably monovalent. In addition, the number of carbon atoms in the aliphatic alcohol used in the present invention is preferably 3 to 23, more preferably 12 to 23, further preferably 17 to 23 from the viewpoint of temporal stability, particularly preferably 19 to 21, and particularly preferably 12 to 20 from the viewpoint of skin permeability. If the number of carbon atoms in the aliphatic alcohol is less than the lower limit, the boiling point becomes low, so it is difficult to keep the content in the preparation constant, and the temporal stability tends to decrease. On the other hand, if the upper limit is exceeded, the compatibility with the adhesive base and other components tends to decrease.
[0063] Examples of the aliphatic alcohols of the present invention include isopropyl alcohol, hexyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, octyldodecanol, oleyl alcohol, linolenic alcohol, and hexyldecanol. One of these may be used alone or two or more of these may be used in combination. Among these, in addition to the above-mentioned viewpoints of stability over time and compatibility, at least one selected from octyldodecanol and lauryl alcohol is particularly preferred as the aliphatic alcohol of the present invention from the viewpoint of particularly improving the skin permeability of rotigotine.
[0064] In the present invention, when the content of the aliphatic alcohol contained in the adhesive layer is two or more, the total amount is preferably 1 to 15% by mass, more preferably 1 to 10% by mass, further preferably 2 to 7% by mass, and particularly preferably 3 to 7% by mass relative to the total mass of the adhesive layer. If the content of the aliphatic alcohol is less than the lower limit, the skin permeability of rotigotine tends to decrease, while if it exceeds the upper limit, the compatibility with the adhesive base and other components tends to decrease.
[0065] <Cross-linked polyvinyl pyrrolidone>
[0066] The adhesive layer according to the present invention further contains cross-linked polyvinyl pyrrolidone (also referred to as "cross-linked PVP" or "cross-linked polyvidone").
[0067] As the cross-linked polyvinyl pyrrolidone of the present invention, cross-linked N-vinyl pyrrolidone polymers can be mentioned. As the above-mentioned N-vinyl pyrrolidone polymer, it can be a homopolymer or a copolymer, for example, a homopolymer of N-vinyl pyrrolidone, a copolymer of N-vinyl pyrrolidone and a multifunctional monomer can be mentioned. Among them, as the cross-linked polyvinyl pyrrolidone of the present invention, a cross-linked homopolymer of 1-vinyl-2-pyrrolidone (also referred to as "cross-linked polyvinyl pyrrolidone") is preferred. As cross-linked polyvinyl pyrrolidone, commercial products such as Coridon CL, Coridon CL-M (manufactured by BASF Japan Co., Ltd.); Polyplasticone XL, Polyplasticone XL-10, Polyplasticone INF-10 (manufactured by ISP Japan Co., Ltd.) can be used.
[0068] In the present invention, the content of cross-linked polyvinyl pyrrolidone contained in the adhesive layer needs to be 10:3 to 1:3 in terms of the mass ratio to the content of rotigotine and / or its pharmaceutically acceptable salt (rotigotine free body conversion content of rotigotine and / or its pharmaceutically acceptable salt: cross-linked polyvinyl pyrrolidone content). If the content of cross-linked polyvinyl pyrrolidone relative to the content of rotigotine and / or its pharmaceutically acceptable salt is less than the above lower limit, crystals of rotigotine and / or its pharmaceutically acceptable salt are precipitated. On the other hand, if the above upper limit is exceeded, it is difficult to achieve excellent skin permeability of rotigotine. The mass ratio (rotigotine free body content of rotigotine and / or its pharmaceutically acceptable salt: cross-linked polyvinyl pyrrolidone content) is preferably 10:3 to 1:2.5, and more preferably 10:3 to 1:2, from the viewpoint of the tendency for better stability over time and skin permeability of rotigotine.
[0069] In addition, the content of cross-linked polyvinyl pyrrolidone contained in the adhesive layer is preferably 3 to 25% by mass, more preferably 3 to 20% by mass, and further preferably 3 to 15% by mass relative to the total mass of the adhesive layer. If the content of cross-linked polyvinyl pyrrolidone is less than the lower limit, crystals of rotigotine and / or a pharmaceutically acceptable salt thereof tend to be easily precipitated, while if the content exceeds the upper limit, the compatibility in the adhesive layer composition during production tends to decrease, making production difficult.
[0070] <Other ingredients>
[0071] The adhesive layer of the present invention may further contain other drugs other than rotigotine and its pharmaceutically acceptable salts; other adhesive bases other than the above-mentioned styrene-based thermoplastic elastomers; thickeners; absorption promoters; adsorbents, desalting agents, plasticizers, solubilizers, fillers, stabilizers, preservatives and other additives within the range not impairing the effects of the present invention.
[0072] (Other drugs)
[0073] Examples of other drugs other than the above-mentioned rotigotine and pharmaceutically acceptable salts thereof include nonsteroidal anti-inflammatory analgesics (diclofenac, indomethacin, ketoprofen, felbinac, loxoprofen, ibuprofen, flurbiprofen, tiaprofen, acemetacin, sulindac, etodolac, tolmetin, piroxicam, meloxicam, ampiroxicam, naproxen, azapropazone, methyl salicylate, glycol salicylate, valdecoxib, celecoxib, rofecoxib, amfenac, etc.), antipyretic analgesics ( Acetaminophen, etc.), antihistamines (diphenhydramine, chlorpheniramine, mequitazine, chlorpheniramine, etc.), antihypertensive agents (diltiazem, nicardipine, nilvadipine, metoprolol, bisoprolol, trandolapril, etc.), anti-Parkinson's agents (pergolide, ropinirole, bromocriptine, selegiline, etc.), bronchodilators (tulobuterol, isoproterenol, salbutamol, etc.), antiallergic agents (ketotifen, loratadine, azelastine, terfenadine, cetirizine, azlast, etc.) , local anesthetics (lidocaine, dibucaine, etc.), drugs for treating neuropathic pain (pregabalin, etc.), non-narcotic analgesics (buprenorphine, tramadol, pentazocine), narcotic analgesics (morphine, oxycodone, fentanyl, etc.), urinary tract agents (oxybutynin, tamsulosin, etc.), psychotropic agents (promazine, chlorpromazine, etc.), steroid hormones (estradiol, progesterone, norethindrone, cortisone, hydrocortisone, etc.), antidepressants (sertraline, fluoxetine, paroxetine , citalopram, etc.), anti-dementia drugs (donepezil, rivastigmine, galantamine, etc.), antipsychotic drugs (risperidone, olanzapine, etc.), central nervous system stimulants (methylphenidate, etc.), osteoporosis therapeutic drugs (raloxifene, alendronate, etc.), breast cancer prevention drugs (tamoxifen, etc.), anti-obesity drugs (mazindol, sibutramine, etc.), insomnia improving drugs (melatonin, etc.), anti-rheumatic drugs (actari, etc.), any one of them may be used alone or in combination of two or more.
[0074] In the present invention, when the adhesive layer further contains these other drugs, the content thereof, when there are two or more types, is preferably 10% by mass or less in total relative to the total mass of the adhesive layer.
[0075] (Other adhesive bases)
[0076] As other adhesive bases other than the above-mentioned styrene-based thermoplastic elastomer, for example, rubber-based adhesive bases other than the above-mentioned styrene-based thermoplastic elastomer, acrylic-based adhesive bases, and silicone-based adhesive bases can be mentioned. One of them can be used alone, or two or more of them can be used in combination.
[0077] As rubber adhesive bases other than the above-mentioned styrene-based thermoplastic elastomer, isoprene rubber, polyisobutylene (PIB), polybutene, etc. can be cited, and one of them can be used alone, or two or more of them can be used in combination. Among them, from the viewpoint of the tendency that the adhesion and cohesive force of the adhesive layer are further improved, polyisobutylene is preferably used, and in this case, the mass ratio of the styrene-based thermoplastic elastomer (more preferably styrene-isoprene-styrene block copolymer) to polyisobutylene (mass of styrene-based thermoplastic elastomer: mass of PIB) is more preferably 1:2 to 30:1 (more preferably in the range of 1:1 to 10:1).
[0078] Examples of the acrylic adhesive base include acrylic acid / octyl acrylate copolymers, 2-ethylhexyl acrylate / vinyl pyrrolidone copolymers, acrylate / vinyl acetate copolymers, 2-ethylhexyl acrylate / 2-ethylhexyl methacrylate / dodecyl methacrylate copolymers, methyl acrylate / 2-ethylhexyl acrylate copolymers, and the like, which are listed as adhesives in the "Dictionary of Pharmaceutical Additives 2016 (Edited by the Japan Pharmaceutical Additives Association)". Resin, 2-ethylhexyl acrylate / methyl acrylate / acrylic acid / glycidyl methacrylate copolymer, 2-ethylhexyl acrylate / vinyl acetate / hydroxyethyl acrylate / glycidyl methacrylate copolymer, 2-ethylhexyl acrylate / diacetone acrylamide / acetoacetoxyethyl methacrylate / methyl methacrylate copolymer, ethyl acrylate / methyl methacrylate copolymer, acrylic polymer contained in acrylic resin alkanolamine liquid, etc., any one of them may be used alone or in combination of two or more.
[0079] Examples of the above-mentioned silicone-based adhesive base include polydimethylsiloxane (polymers represented by MQ in the expression using ASTM D-1418, etc.), polymethylvinylsiloxane (polymers represented by VMQ in the expression using ASTM D-1418, etc.), polymethylphenylsiloxane (polymers represented by PVMQ in the expression using ASTM D-1418, etc.), and the like. Any one of them may be used alone, or two or more of them may be used in combination.
[0080] In the present invention, when these other adhesive bases are further contained, the content thereof, when two or more types are present, is preferably 10% by mass or less in total relative to the total mass of the adhesive layer.
[0081] (Thickener)
[0082] The above-mentioned tackifier is mainly formulated for the purpose of improving the adhesion of the above-mentioned adhesive base. As the above-mentioned tackifier, tackifier resins other than the above-mentioned petroleum resins and terpene resins can be cited, for example, rosin resins, phenol resins and xylene resins, and one of them can be used alone, or two or more can be used in combination. In the present invention, when these tackifiers are also contained, as their content, when there are two or more, the total amount is preferably less than 10% by mass relative to the total mass of the above-mentioned adhesive layer.
[0083] (Absorption enhancers (transdermal absorption enhancers))
[0084] As the absorption enhancer, there can be mentioned substances having a drug percutaneous absorption enhancing effect other than the aliphatic alcohol, for example, fatty acids, fatty acid esters, fatty acid amides, or aliphatic alcohol ethers having 6 to 20 carbon atoms; aromatic organic acids; aromatic alcohols; aromatic organic acid esters or ethers; POE hydrogenated castor oils; lecithins; phospholipids; soybean oil derivatives; triacetin, and one of them can be used alone or in combination of two or more. In the present invention, when these absorption enhancers are also contained, their content, when there are two or more, is preferably 10% by mass or less in total relative to the total mass of the adhesive layer.
[0085] (additive)
[0086] 〔Adsorbent〕
[0087] As the above-mentioned adsorbent, there can be mentioned inorganic and / or organic substances with hygroscopicity, more specifically, there can be mentioned minerals such as talc, kaolin, bentonite, etc.; silicon compounds such as pyrogenic silica (アエロジル (registered trademark) and hydrous silica); metal compounds such as zinc oxide and dried aluminum hydroxide gel; weak acids such as lactic acid and acetic acid; sugars such as dextrin; high molecular polymers such as polyvinyl pyrrolidone (non-crosslinked PVP), aminoalkyl methacrylate copolymers, carboxyvinyl polymers and butyl methacrylate methyl methacrylate copolymers, and one of them can be used alone or in combination of two or more. In the present invention, when the above-mentioned adhesive layer also contains these adsorbents, as their content, when there are two or more, the total amount is preferably 10% by mass or less relative to the total mass of the above-mentioned adhesive layer.
[0088] 〔Desalting agent〕
[0089] The above-mentioned desalting agent is mainly matched with the purpose of converting all or part of the alkaline drug into a free body. As such a desalting agent, there is no particular limitation. For example, in the case of obtaining a preparation of a drug containing a free body by using an acid addition salt of a drug as the above-mentioned drug, it is preferably an alkaline substance, more preferably a desalting agent containing metal ions, a desalting agent containing a basic nitrogen atom. As the above-mentioned desalting agent containing metal ions, sodium acetate (including anhydrous sodium acetate), sodium hydroxide, potassium hydroxide, magnesium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium citrate, sodium lactate, etc. can be cited. One of them can be used alone, or two or more can be used in combination. In addition, as the adhesive layer involved in the present invention, a compound derived from the above-mentioned alkaline drug and the above-mentioned desalting agent can also be contained (for example, sodium chlorate when rotigotine hydrochloride is combined with sodium acetate). In the present invention, when the adhesive layer further contains these desalting agents and compounds derived from the basic drug and the desalting agent, the content thereof, when two or more types are contained, is preferably 10% by mass or less in total relative to the total mass of the adhesive layer.
[0090] 〔Plasticizer〕
[0091] The above-mentioned plasticizer is mainly formulated for the purpose of adjusting the adhesive properties of the above-mentioned adhesive layer, the flow characteristics in the manufacture of the above-mentioned adhesive layer, the percutaneous absorption characteristics of the above-mentioned drug, etc. As such a plasticizer, for example, silicone oil; petroleum oils such as paraffin processing oil, cycloparaffin processing oil and aromatic processing oil; squalane, squalene; plant oils such as olive oil, camellia oil, castor oil, tall oil and peanut oil; dibasic acid esters such as dibutyl phthalate and dioctyl phthalate; liquid rubbers such as polybutene and liquid isoprene rubber; diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, etc., and one of them can be used alone, or two or more can be used in combination. Among them, as the above-mentioned plasticizer, silicone oil, liquid paraffin, and liquid polybutene are preferred. In the present invention, when the above-mentioned adhesive layer also contains these plasticizers, from the viewpoint of improving the adhesive strength of the adhesive layer and / or alleviating the local irritation during peeling, their content, when there are two or more types, is preferably 5 to 30% by mass, more preferably 10 to 20% by mass, relative to the total mass of the above-mentioned adhesive layer.
[0092] 〔Dissolving agent / filling agent〕
[0093] As the above-mentioned dissolving agent, for example, organic acids such as acetic acid and surfactants can be mentioned, and one of them can be used alone or two or more of them can be used in combination. In addition, the above-mentioned filler is mainly mixed for the purpose of adjusting the adhesion of the above-mentioned adhesive layer. As the filler, for example, aluminum hydroxide, calcium carbonate, magnesium carbonate; silicates such as aluminum silicate and magnesium silicate; silicic acid, barium sulfate, calcium sulfate, calcium zincate, zinc oxide, titanium oxide can be mentioned, and one of them can be used alone or two or more of them can be used in combination.
[0094] 〔Stabilizer〕
[0095] Examples of the stabilizer include ascorbic acid or a metal salt or ester thereof (preferably a sodium salt or palmitate), isoascorbic acid or a metal salt thereof (preferably a sodium salt), ethylenediaminetetraacetic acid or a metal salt thereof (preferably a calcium disodium salt or a tetrasodium salt), cysteine, acetylcysteine, 2-mercaptobenzimidazole, dibutylhydroxytoluene, butylated hydroxyanisole, propyl gallate, pentaerythritol-tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate], 3-mercapto-1,2-propanediol, tocopherol acetate, thymol, soybean lecithin, rutin, dihydroxybenzoic acid, potassium dichloroisocyanurate, quercetin, hydroquinone, a hydroxymethanesulfinic acid metal salt (preferably a sodium salt), a pyrosulfite metal salt (for example, a sodium salt), a sulfite metal salt (preferably a sodium salt), and a thiosulfate metal salt (preferably a sodium salt). Any one of these may be used alone or in combination of two or more. Among the above, examples of the metal salt include sodium salt, potassium salt, calcium salt, and magnesium salt, and examples of the ester include palmitic acid ester, stearic acid ester, and myristic acid ester.
[0096] In the present invention, from the viewpoint of further improving the stability over time, it is preferred that the adhesive layer further contains the stabilizer. In this case, the content of the stabilizer is preferably 0.001 to 5% by mass, more preferably 0.005 to 3% by mass, and more preferably 0.01 to 2% by mass relative to the total mass of the adhesive layer in the case of two or more kinds. If the content of the stabilizer exceeds the upper limit, there is a possibility that the physical properties such as the adhesion of the adhesive layer are reduced. If it is less than the lower limit, there is a tendency that the stabilization effect brought by the stabilizer cannot be fully exerted.
[0097] 〔Preservative〕
[0098] Examples of the preservative include p-hydroxybenzoic acid derivatives, benzyl alcohol, phenol, cresol, and the like. These may be used alone or in combination of two or more.
[0099] When the adhesive layer further contains the additives, the content thereof, when two or more types are present, is preferably 40% by mass or less, more preferably 30% by mass or less, based on the total mass of the adhesive layer.
[0100] The adhesive layer of the present invention is not particularly limited, but the weight per unit area (the area of the bonding surface) is preferably 20 to 200 g / m 2 , more preferably 30 to 100 g / m 2 , more preferably 30 to 70 g / m 2 In addition, the area of the adhesive surface of the adhesive layer of the present invention can be appropriately adjusted according to the purpose of treatment and the applicable object, and is not particularly limited, but is usually 0.5 to 200 cm 2 range.
[0101] The patch containing rotigotine of the present invention is not particularly limited and can be manufactured by appropriately adopting a known method for manufacturing a patch. For example, first, rotigotine and / or its pharmaceutically acceptable salt, the above-mentioned styrene-based thermoplastic elastomer, the above-mentioned petroleum-based resin and / or terpene-based resin, the above-mentioned aliphatic alcohol, cross-linked polyvinyl pyrrolidone, and the solvent as required, the above-mentioned other components are kneaded according to a conventional method to obtain a uniform adhesive layer composition. In the case of using rotigotine free body as the above-mentioned rotigotine and / or its pharmaceutically acceptable salt, it can be its type I crystal, it can also be type II crystal, it can also be amorphous, it can also be a mixture of at least two or more of type I crystal, type II crystal, and amorphous. In addition, as the above-mentioned rotigotine and / or its pharmaceutically acceptable salt, the above-mentioned substance dissolved in a solvent can be used. As the above-mentioned solvent, anhydrous ethanol, toluene, heptane, methanol, ethyl acetate, hexane, and a mixed solution of at least two or more of them can be cited.
[0102] Next, the adhesive layer composition can be applied on the surface of the support layer (usually on one surface) in a manner to obtain a desired mass per unit area, and then heated to dry and remove the solvent as needed to form an adhesive layer, and further cut into a desired shape as needed to obtain the patch of the present invention.
[0103] In addition, the method for producing the patch containing rotigotine of the present invention may further include a step of laminating the release liner on the surface of the adhesive layer opposite to the support layer, or the adhesive layer may be formed by first applying the adhesive layer composition to one surface of the release liner in a desired mass per unit area, laminating the support layer on the surface of the adhesive layer opposite to the release liner, and cutting into a desired shape as needed to obtain the patch of the present invention. Furthermore, the obtained patch may be sealed in a storage packaging container (e.g., an aluminum laminate bag) as needed to form a package.
[0104] Example
[0105] Hereinafter, the present invention will be described in more detail based on Examples and Comparative Examples, but the present invention is not limited to the following Examples. In addition, in each Example and Comparative Example, the skin permeation test, crystallization evaluation, and differential scanning calorimetry were performed by the methods shown below.
[0106] <Skin permeation test (in vitro hairless mouse skin permeation test)>
[0107] First, the skin of the trunk of a hairless mouse was peeled off and the fat removed, and a 1.0 cm thick piece of skin was applied to the stratum corneum side of the fat-removed skin piece. 2 A test sample was prepared by placing a square patch with the release liner removed. The patch was placed in a flow-through diffusion cell in such a way that the dermis side was in contact with the receiving solution, and the receiving solution (phosphate buffered saline) was filled in the diffusion cell. Next, the receiving solution was kept warm at 32°C, while warm circulating water was circulated in the periphery, and the receiving solution was transported at a flow rate of about 5 mL / hr, and the receiving solution was taken every 2 hours until 24 hours. The rotigotine concentration in the obtained receiving solution was determined by high performance liquid chromatography, and the rotigotine skin permeation amount per unit area of the adhesive layer was calculated by the following formula, and the skin permeation amount per hour (skin permeation rate (μg / cm 2 The two test samples were measured, and the average of the maximum values of the skin permeation rates within 24 hours was defined as the maximum skin permeation rate (Jmax).
[0108] Rotigotine skin permeation (μg / cm 2 ) = {rotigotine concentration in receiving solution (μg / mL) × flow rate (mL)} / patch area (cm 2 )
[0109] <Crystallization evaluation>
[0110] The patch obtained in each embodiment and comparative example is sealed in an aluminum laminated pressed bag to make a test sample, which is stored at room temperature (about 25°C) for 3 days or 6 months, and the surface of the adhesive layer after storage is observed visually and under an optical microscope. The crystallization precipitation state on the surface of each adhesive layer and the presence or absence of amorphous particles are evaluated based on the following benchmarks. The evaluation is performed on 2 test samples respectively, but there is no difference between the 2 test samples obtained in each of the following embodiments and comparative examples, which is the evaluation result shown in the following tables.
[0111] A: Neither crystalline particles nor amorphous particles can be observed visually or under an optical microscope.
[0112] B: Crystalline particles and / or amorphous particles are observed visually or with an optical microscope
[0113] <Differential Scanning Calorimetry (DSC Measurement)>
[0114] First, regarding the type I crystal and type II crystal of rotigotine (free form), DSC measurement was performed using a differential scanning calorimeter ("Q-2000", manufactured by TA Instrument Co., Ltd.) at a heating rate of 10°C / min from 10°C to 120°C. The endothermic melting point peak (melting point) was determined from the peak observed in the obtained differential thermal analysis chart, and the results showed that the endothermic melting point peak was 78.56°C for type I and 97.40°C for type II. Figure 1 The DSC results of the free form of rotigotine, Figure 2 The DSC measurement results of the type II crystals of free rotigotine are shown in FIG.
[0115] Next, cut out the end of each patch just after manufacture and 6 months after manufacture (the patch is sealed in an aluminum laminated bag and stored at room temperature (about 25°C) for 6 months), use a micro-spatula to peel off the adhesive layer from the support layer, and seal it in a sealed dish. While heating it from 10°C to 120°C at a heating rate of 10°C / min using the above-mentioned differential scanning calorimeter, DSC measurement was performed, and endothermic melting point peaks and baseline drifts near 78.56°C and 97.4°C were observed. In addition, when an endothermic melting point peak is observed in the differential thermal analysis diagram obtained by DSC measurement, it indicates that the drug contained in the adhesive layer is crystalline, and when a baseline drift is observed, it indicates that the drug contained in the adhesive layer is amorphous, and when neither is observed, it indicates that the drug contained in the adhesive layer is completely dissolved.
[0116] (Example 1)
[0117] First, 9.0 parts by mass of rotigotine (free body), 14.5 parts by mass of styrene-isoprene-styrene block copolymer, 6.2 parts by mass of polyisobutylene, 45.7 parts by mass of alicyclic saturated hydrocarbon resin, 16.6 parts by mass of liquid paraffin, 5 parts by mass of octyldodecanol, and 3 parts by mass of cross-linked polyvinyl pyrrolidone (cross-linked PVP) were added to an appropriate amount of solvent (anhydrous ethanol and toluene) and mixed to obtain an adhesive layer composition. Then, the obtained adhesive layer composition was coated on a release liner (polyethylene terephthalate film with demolding treatment), and the solvent was dried and removed to a mass per unit area of 50 g / m 2 A support layer (polyethylene terephthalate film) was laminated on the surface of the obtained adhesive layer opposite to the release liner to obtain a patch laminated in the order of support layer / adhesive layer / release liner.
[0118] (Examples 2 to 3, Comparative Examples 1 to 3)
[0119] Each patch was obtained in the same manner as in Example 1 except that the composition of the adhesive layer composition was changed to the composition shown in Table 1 below.
[0120] The patches obtained in Examples 1 to 3 and Comparative Examples 1 to 3 were subjected to skin permeation tests and crystallization evaluation (3 days after production). The results are shown in Table 1 together with the composition of the adhesive layer composition (excluding the solvent) of each Example and Comparative Example.
[0121] Table 1
[0122]
[0123] In the patches obtained in Examples 1 to 3, no crystalline or amorphous particles were confirmed even 3 days after production. In addition, DSC measurement of the adhesive layer was performed on the patches obtained in Examples 1 to 3. As a result, no endothermic melting point peak derived from crystallization and no baseline drift due to glass transition derived from amorphous material were observed immediately after production and 6 months after production, confirming that rotigotine was completely contained in the adhesive layer in a dissolved form. Figure 3 6 months after the manufacture, the adhesive layer of the patch obtained in Example 3 was subjected to DSC measurement. On the other hand, in the patches obtained in Comparative Examples 1 to 3, precipitation of crystals was confirmed from immediately after manufacture. In addition, regarding the patches obtained in Comparative Examples 1 to 3, DSC measurement was performed on the adhesive layer of the patches immediately after manufacture, and an endothermic melting point peak derived from crystals was observed.
[0124] (Comparative Examples 4 to 11)
[0125] Each patch was obtained in the same manner as in Example 1 except that the composition of the adhesive layer composition was set to the composition shown in Table 2 below. In Table 2, "KE-311 (manufactured by Arakawa Chemical Industries, Ltd.)" was used as hydrogenated rosin ester, "Oidragon (manufactured by Ebonick)" was used as aminoalkyl methacrylate copolymer E, "Coridon VA-64 (manufactured by BASF)" was used as vinyl acetate / vinyl pyrrolidone copolymer, and "Soluplus (manufactured by BASF)" was used as polyvinyl caprolactam / polyvinyl acetic acid / polyethylene glycol graft copolymer.
[0126] The patches obtained in Comparative Examples 4 to 11 were subjected to skin permeation tests and crystallization evaluation (3 days after manufacture). The results are shown in Table 2 together with the composition of the adhesive layer composition of each comparative example (excluding the solvent). In Table 2, the maximum skin permeation rate is expressed as a value when the maximum skin permeation rate in the above-mentioned Example 3 is set to 100, and the composition of the adhesive layer composition of Example 3 as a reference, as well as the results of the skin permeation test and crystallization evaluation are shown together in Table 2.
[0127] Table 2
[0128]
[0129] (Reference Examples 1 to 21)
[0130] Each patch was obtained in the same manner as in Example 1 except that the composition of the adhesive layer composition was changed to the composition shown in the following Table 3. As the absorption enhancers described in Table 3, the absorption enhancers shown in the following Table 4 were used.
[0131] The compositions of the adhesive layer compositions in Reference Examples 1 to 21 (excluding the solvent) are shown in Table 3. In addition, the results of the skin permeation test and crystallization evaluation (3 days after production) of the patches obtained in Reference Examples 1 to 21 are shown in Table 4 together with the absorption enhancers used in each Reference Example.
[0132] Table 3
[0133]
[0134] Table 4
[0135]
[0136] As shown in the DSC test results and Table 1 and Figures 1 to 3 As shown, it was confirmed that in the patch of the present invention, the drug is contained in a dissolved form in the adhesive layer immediately after production, the precipitation of crystals is suppressed even after storage, and a high level of skin permeability is achieved.
[0137] On the other hand, when no cross-linked polyvinyl pyrrolidone was contained or when the content of cross-linked polyvinyl pyrrolidone exceeded the range of the present invention (Comparative Examples 1 to 3), rotigotine crystals precipitated. When a solubilizing agent having a function of dissolving crystals, which is known to have been used in place of cross-linked polyvinyl pyrrolidone, was used (Comparative Examples 5 to 11), as shown in Table 2, although no crystal precipitation of rotigotine was confirmed, the skin permeability of rotigotine was greatly reduced. In addition, when hydrogenated rosin ester was used as a tackifier instead of alicyclic saturated hydrocarbon resin (Comparative Example 4), the skin permeability of rotigotine was also greatly reduced. Furthermore, when no aliphatic alcohol was contained (Comparative Example 1), the skin permeability of rotigotine was confirmed to be greatly reduced. In addition, when other absorption enhancers were used instead of aliphatic alcohol (Reference Examples 10 to 21), it was suggested that the skin permeability of rotigotine was reduced.
[0138] (Examples 4 to 6)
[0139] Each patch was obtained by the same operation as in Example 1 except that the composition of the adhesive layer composition was the composition shown in Table 5 below. The patches obtained in Examples 4 to 6 were subjected to skin permeation tests and crystallization evaluation (6 months after manufacture). The results are shown in Table 5 together with the composition of the adhesive layer composition of each example (excluding the solvent).
[0140] Table 5
[0141]
[0142] As shown in Table 5, in the patches obtained in Examples 4 to 6, no crystalline or amorphous particles were confirmed even 6 months after the production.
[0143] (Examples 7 to 8, Comparative Example 12)
[0144] Each patch was obtained in the same manner as in Example 1 except that the composition of the adhesive layer composition was set to the composition shown in the following Table 6. In Table 6, "YS resin PX1150N (manufactured by Yashara Chemical Co., Ltd.)" was used as the terpene resin, and "KE-311 (manufactured by Arakawa Chemical Industries, Ltd.)" was used as the hydrogenated rosin ester.
[0145] The patches obtained in Examples 7 to 8 and Comparative Example 12 were subjected to skin permeation tests and crystallization evaluations (six months after manufacture). In addition, in the crystallization evaluation, the surface of the adhesive layer after storage was visually observed only, and the surface state of each adhesive layer was evaluated based on the following criteria. The results are shown in Table 6 together with the composition (excluding the solvent) of the adhesive layer composition of each Example and Comparative Example.
[0146] A: No particles can be observed visually (crystalline particles and amorphous particles)
[0147] B: Particles (crystalline particles and / or amorphous particles) are observed visually.
[0148] Table 6
[0149]
[0150] As shown in Table 6, in the patches obtained in Examples 7 to 8 using petroleum resins and terpene resins, it was confirmed that the precipitation of crystals was suppressed even after storage and a high level of skin permeability was achieved. However, in the case of using hydrogenated rosin ester (Comparative Example 12), it was confirmed that the skin permeability of rotigotine was greatly reduced as in Comparative Example 4.
[0151] (Examples 9 to 12)
[0152] The composition of the adhesive layer composition was made to be the composition shown in Table 7 below, and the same operation as in Example 1 was performed to obtain each patch. The patches obtained in Examples 9 to 12 were subjected to skin permeation test and crystallization evaluation (after 3 days of manufacture). In addition, in the crystallization evaluation, the storage period was 3 days, and the same operation as in Examples 7 to 8 and Comparative Example 12 was performed. The results are shown in Table 7 together with the composition (excluding solvent) of the adhesive layer composition of each embodiment.
[0153] Table 7
[0154]
[0155] As shown in Table 7, in the patches obtained in Examples 9 to 12 using aliphatic alcohols, it was confirmed that precipitation of crystals was suppressed even after storage and that a high level of skin permeability was achieved.
[0156] (Examples 13-14)
[0157] The composition of the adhesive layer composition was made as shown in Table 8 below, and each patch was obtained in the same manner as in Example 1. The patches obtained in Examples 13 to 14 and the patches obtained in Example 6 were subjected to skin permeation tests and crystallization evaluations (3 days after manufacture). In addition, in the skin permeation test, instead of the fat-removed skin slices of the trunk of hairless mice, the frozen human skin slices were thawed at room temperature, and after removing the subcutaneous fat, the fat-removed skin slices of about 500 μm thickness were cut using a skin extractor. In addition, in the crystallization evaluation, the storage period was 3 days, and the same operation was performed as in Examples 7 to 8 and Comparative Example 12. The results are shown in Table 8 together with the composition of the adhesive layer composition of each embodiment (excluding the solvent). In Table 8, the maximum skin permeation rate is represented by the value when the maximum skin permeation rate in Example 6 is set to 100, and the composition of the adhesive layer composition of Example 6 as a reference is shown in Table 8.
[0158] Table 8
[0159]
[0160] As shown in Table 8, in the patches obtained in Examples 13 to 14, similarly to the patch obtained in Example 6, it was confirmed that the precipitation of crystals was suppressed even after storage and that a high level of skin permeability was achieved.
[0161] Industrial Availability
[0162] As described above, according to the present invention, a rotigotine-containing patch can be provided which contains rotigotine and / or a pharmaceutically acceptable salt thereof in a dissolved form in an adhesive layer and has excellent stability over time and skin permeability of rotigotine.
Claims
1. A rotigotine-containing patch comprising a support layer and an adhesive layer, wherein the adhesive layer contains rotigotine and / or a pharmaceutically acceptable salt thereof. It is characterized in that The adhesive layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and / or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinyl pyrrolidone, and In the adhesive layer, the mass ratio of the content of rotigotine and / or its pharmaceutically acceptable salt converted into rotigotine free body to the content of cross-linked polyvinyl pyrrolidone, i.e., the content of rotigotine free body of rotigotine and / or its pharmaceutically acceptable salt converted into rotigotine: the content of cross-linked polyvinyl pyrrolidone is 10:3 to 1:3, Furthermore, the styrene-based thermoplastic elastomer is a styrene-based block copolymer, the petroleum-based resin is an alicyclic saturated hydrocarbon resin, and the terpene-based resin is a pinene polymer. The content of the petroleum-based resin and / or the terpene-based resin in the adhesive layer is 10 to 60% by mass based on the total mass of the adhesive layer.
2. The rotigotine-containing patch according to claim 1, characterized in that: The adhesive layer contains rotigotine and / or a pharmaceutically acceptable salt thereof in a dissolved form.
3. The rotigotine-containing patch according to claim 1 or 2, characterized in that: The aliphatic alcohol has 12 to 23 carbon atoms.
4. The rotigotine-containing patch according to claim 1 or 2, characterized in that: The content of rotigotine and / or a pharmaceutically acceptable salt thereof in the adhesive layer is 5 to 15% by mass in terms of free rotigotine based on the total mass of the adhesive layer.
5. The rotigotine-containing patch according to claim 1 or 2, characterized in that: The content of the aliphatic alcohol in the adhesive layer is 1 to 15% by mass based on the total mass of the adhesive layer.
6. The rotigotine-containing patch according to claim 1 or 2, characterized in that: The adhesive layer further contains a stabilizer.
